TrumpRx.gov launches and becomes a .gov competitor for drug-pricing queries

The federal government launched TrumpRx.gov on February 5, 2026, a site that displays discounted cash prices for dozens of brand-name drugs, including the GLP-1 medicines Ozempic, Wegovy and Zepbound ^[1][2]. The site says it has already saved Americans more than $700 million ^[1], and it entered a search landscape long dominated by coupon sites like GoodRx and SingleCare and by telehealth blogs.

According to a White House fact sheet, the launch features drugs from the first five manufacturers to sign so-called most-favored-nation (MFN) pricing deals with the administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer ^[2]. The fact sheet says the monthly price of Ozempic will fall from $1,028 to an average of $350, and as low as $199 depending on dosage ^[2]. Injectable Wegovy is listed at the same average, $350, with prices as low as $199, while the Wegovy pill drops from $1,349 to as low as $149 depending on strength ^[1][2]. Zepbound's list price of $1,088 is shown falling to an average of $346, with prices as low as $299 ^[1][2]. The site itself displays Ozempic at $199 per month against a $1,028 list price, Wegovy pen at $199 against $1,349, Wegovy pill at $149 against $1,349, and Zepbound at $299 against $1,087 ^[1].

The fact sheet frames these reductions as flowing from a broader MFN pricing push that began with a May 12, 2025 executive order and continued through 16 manufacturer deals announced since September 30, 2025 ^[2]. It also cites non-GLP-1 examples, such as an inhaler called Bevespi Aerosphere dropping from $458 to $51, and the fertility drug Cetrotide falling from $316 to $22.50 ^[2].

TrumpRx.gov is not a pharmacy. Its own FAQ section poses questions such as "What is TrumpRx?", "Do I need to create an account or register on TrumpRx?", "Can I use my insurance to buy drugs listed on TrumpRx?" and "How do I purchase drugs at TrumpRx?" ^[1]. The site's structure shows that patients access savings either through printable or downloadable coupons or through pathways set up by drug manufacturers and connected to the site, depending on which company makes the drug ^[2]. The source pages reviewed do not include the answer text for several of these FAQ items, including the insurance question, so it is not yet known from these materials exactly how insurance coverage interacts with the listed prices.

Why it matters for patients

For people paying cash for semaglutide or tirzepatide, the price gaps shown are large. Ozempic at $199 to $350 a month, instead of $1,028, or Zepbound at $299 to $346 instead of $1,088, could change what a course of treatment costs out of pocket ^[1][2]. But the site works through prescriptions and manufacturer coupon or discount channels rather than direct sales, and the FAQ list itself signals that many basic questions, like whether a local pharmacy can honor these prices or whether insurance can be combined with the discount, are things patients will need to look into before assuming a price applies to them ^[1]. Because TrumpRx.gov entered a search results space previously dominated by private coupon sites and telehealth blogs, patients researching drug prices online may now encounter a government-run option alongside those private ones, without a clear built-in explanation, in the materials reviewed, of how the .gov site's coupons differ in practice from a discount card from GoodRx or SingleCare.

What happens next

The fact sheet says additional drugs from other manufacturers that have signed MFN pricing deals will be added to TrumpRx.gov "in the coming months," though no specific dates are given ^[2]. The White House has also referenced planned expansions of the site's scope, including a February 6, 2026 release and a fact sheet dated May 18, 2026 describing an expansion toward "everyday medicines," but the source materials here do not detail what changes those updates will include for GLP-1 pricing specifically ^[2].